Mineralys Therapeutics, Inc.

Mineralys ended Q2 2026 with cash, cash equivalents, and investments of $661.4 million as of 6/30/2026, versus $656.6 million at 12/31/2025. The company said that cash is sufficient to fund planned operations, including the commercial launch of lorundrostat, into 2028. R&D expense was $221.4 million, up from $38.3 million a year earlier, mainly due to the $200 million upfront payment to Mitsubishi Tanabe, plus smaller increases in personnel and other costs; G&A expense was $24.7 million versus $8.5 million. Total other income, net was $5 million versus $3.5 million, and net loss was $241.1 million versus $43.3 million. No next-quarter revenue or EPS guidance was given; management reiterated focus on the December 22 PDUFA date and said launch readiness and commercial staffing should be in place ahead of approval.

Jon Congleton struck an upbeat, execution-focused tone, emphasizing that the quarter was about commercial readiness, strategic capital moves, and extending lorundrostat’s clinical story. He highlighted the addition of Terry Ferguson as CMO, saying Ferguson’s cardiovascular and medical affairs background strengthens the team as the company prepares for potential commercialization. He also framed the asset as entering an important new phase, with continuing work on partnering and possible future clinical development in cardiorenal-metabolic disease.

Adam Scott Levy focused on liquidity and the cost impact of strategic actions. He said the company held $661.4 million in cash, cash equivalents, and investments at quarter-end and believes that is enough to support operations and launch into 2028. On the P&L, he pointed to R&D of $221.4 million and G&A of $24.7 million, with the R&D spike driven primarily by the $200 million upfront royalty repurchase payment to Mitsubishi Tanabe. Other income rose to $5 million, helped by interest income, while net loss was $241.1 million.

Analysts pressed on hiring for the field force, payer access, pricing, and what the early baxdrostat launch means for Mineralys. Management said it is comfortable with candidate quality and expects the sales team to be in place ahead of the PDUFA date, while payer conversations have been positive and access looks consistent with expectations. On pricing, the company said baxdrostat’s price was not a surprise, that it likely will not disclose its own price until approval or launch, and that it is still finalizing strategy while aiming to preserve value. On label strategy, management said it expects discussions with FDA in the October-November timeframe and believes launch HTN, Advanced-HTN, and explore CKD could help support differentiation, including kidney-function language and hyperkalemia data.